Scholarlink

<p><?tk 4?>Cholestatic liver disease occurs due to&#xa0;deficiencies in bile production, secretion, and passage via the biliary system. Cholestatic liver is therapeutic challenge due to limited treatment options and incomplete understanding of its pathophysiology. Myrtenol, which exists in the essential oils of some medicinal plants such as <i>Myrtus communis, Artemisia</i>&#xa0;and&#xa0;<i>Eucalyptus</i>—has demonstrated anti-inflammatory, antioxidant. Our aim of this study was to investigate the effect of myrtenol on liver damage in male rats with intrahepatic and extrahepatic cholestasis. Forty-eight male Wistar rats were randomly divided into two main groups: intrahepatic and extrahepatic cholestasis groups. In the intrahepatic cholestasis group, intrahepatic injury was elicited by intraperitoneal (IP) injection of acetaminophen (500 mg/kg) and included four subgroups: 1. Sham, 2. Acetaminophen (Aceta), 3. Dimethyl sulfoxide (Aseta + DMSO), and 4. Myrtenol (Aseta + Myr). The extrahepatic cholestasis group was induced by common bile duct litigation (BDL) and included four subgroups: (1) Sham, (2) BDL, (3) DMSO, and (4) Myrtenol (BDL + Myr). Myrtenol was administered intraperitoneally for six days. Blood samples and liver samples, were taken for biochemical and histological evaluations. The findings showed that Myrtenol significantly attenuated the increase in liver enzymes, pro-inflammatory cytokines, and oxidant levels caused by intra- and extra-hepatic cholestasis. Myrtenol also increased the decrease in hepatic antioxidant biomarkers. Myrtenol shows promise in reducing cholestatic liver injury by reducing liver enzymes, inflammation, and oxidative stress while restoring antioxidant defenses. However, further preclinical and clinical studies are necessary to confirm its therapeutic potential for human cholestatic diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the Modifying impact of myrtenol on intrahepatic cholestasis and extrahepatic cholestasis in male rats: role of oxidative stress and inflammation

  • 期刊论文

  • 发表日期：

    2025年10月15日

查看全文
  • Mohammad Amin Rajizadeh,
  • Masoumeh Ghasemi,
  • Mohammad Abbas Bejeshk,
  • Mohammad Akhbari,
  • Shadan Saberi,
  • Fatemeh Bagheri,
  • Sedigheh Amiresmaili

摘要

Cholestatic liver disease occurs due to deficiencies in bile production, secretion, and passage via the biliary system. Cholestatic liver is therapeutic challenge due to limited treatment options and incomplete understanding of its pathophysiology. Myrtenol, which exists in the essential oils of some medicinal plants such as Myrtus communis, Artemisia and Eucalyptus—has demonstrated anti-inflammatory, antioxidant. Our aim of this study was to investigate the effect of myrtenol on liver damage in male rats with intrahepatic and extrahepatic cholestasis. Forty-eight male Wistar rats were randomly divided into two main groups: intrahepatic and extrahepatic cholestasis groups. In the intrahepatic cholestasis group, intrahepatic injury was elicited by intraperitoneal (IP) injection of acetaminophen (500 mg/kg) and included four subgroups: 1. Sham, 2. Acetaminophen (Aceta), 3. Dimethyl sulfoxide (Aseta + DMSO), and 4. Myrtenol (Aseta + Myr). The extrahepatic cholestasis group was induced by common bile duct litigation (BDL) and included four subgroups: (1) Sham, (2) BDL, (3) DMSO, and (4) Myrtenol (BDL + Myr). Myrtenol was administered intraperitoneally for six days. Blood samples and liver samples, were taken for biochemical and histological evaluations. The findings showed that Myrtenol significantly attenuated the increase in liver enzymes, pro-inflammatory cytokines, and oxidant levels caused by intra- and extra-hepatic cholestasis. Myrtenol also increased the decrease in hepatic antioxidant biomarkers. Myrtenol shows promise in reducing cholestatic liver injury by reducing liver enzymes, inflammation, and oxidative stress while restoring antioxidant defenses. However, further preclinical and clinical studies are necessary to confirm its therapeutic potential for human cholestatic diseases.